Trial Profile

A Phase 1/2 Study of the Bromodomain Inhibitor ZEN003694 in Combination With Etoposide/Platinum in Patients With NUT Carcinoma

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 13 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cisplatin (Primary) ; Etoposide (Primary) ; ZEN 3694 (Primary)
Indications Cancer; Carcinoma
Focus Adverse reactions; Therapeutic Use

Most Recent Events

07 Jan 2026 Phase I\II amended to phse I.
18 Dec 2025 Planned number of patients changed from 55 to 36.
18 Dec 2025 Phase 1\2 has been changed to phase 1,study design changed to Parallel ,non-randomized ,no of arms increased to 3.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com